Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
bioMérieux S.A (BMXMF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of bioMérieux S.A $83.43, price $85.00, upside -1.9%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
BS
Broad data
Oct 3, 2026
Broad data
Oct 3, 2026
bioMérieux S.A
BMXMF · USNeutralThe stock looks roughly fairly valued with average quality.
·Fair value $83.43 · Fairly valued (−1.9%)
✓Quality 69/100
✓Healthy Growth (revenue 5y +5.5 %/yr)
!Thin margins · 9.8% net margin (TTM)
✓Low debt · generates free cash flow
✓1.2% dividend yield · Well covered
!Moderate moat 59/100
Watch bioMérieux S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $32.06 – $159.63 · fair‑value band $57.55 – $104.29 · the $85.00 price screens above the $83.43 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments.
Show more
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Stock analysis
bioMérieux S.A (BMXMF) currently trades at $85.00, while our model-based Fair Value estimate is $83.43, so the stock looks roughly fairly valued today (gap 1.9%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $87.29 per share, and 9 of the 26 models we run sit above the $85.00 price.
Bear case: the Dividend Discount group reads lowest at $14.92, and 17 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $57.55 (bear) to $104.29 (bull), the price of $85.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
bioMérieux S.A reported revenue of €4.1B in FY2025 versus €3.4B in FY2021, a compound +4.8%/yr. Reported net income was €397M in FY2025, compounding −9.8%/yr from FY2021.
Key figures
Market cap $10.1B · P/E ratio 21.9 · P/S ratio 2.14 · EPS (TTM) $3.88 · Dividend yield 1.2% · Net margin 9.8% · Return on equity 9.5% · Return on assets (EBIT) 11.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −2%, BMXMF screens cheaper than that median.
Fair Value models
Bear $57.55
Fair Value $83.43
Bull $104.29
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.19 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$52.26
$79.51
$120.22
80
Growth DCF
$52.77
$76.42
$109.41
78
Owner Earnings
$57.25
$87.29
$132.16
76
All 26 models by family
DCF Models
FCF DCF
$52.26
$79.51
$120.22
80
Owner Earnings
$57.25
$87.29
$132.16
76
5Y Revenue Exit
$55.82
$89.43
$132.77
72
5Y EBITDA Exit
$83.70
$142.35
$211.90
74
5Y P/E Exit
$56.78
$91.25
$127.82
70
10Y Revenue Exit
$52.31
$82.40
$123.67
66
10Y EBITDA Exit
$71.47
$118.59
$183.52
67
10Y P/E Exit
$54.59
$83.64
$119.93
64
Earnings-Based
Graham-Dodd
$25.79
$86.10
$115.28
64
Lynch FV
$19.54
$27.91
$36.28
61
PEG = 1.0
$19.54
$27.91
$36.28
57
EPV
$49.03
$56.23
$62.45
74
Dividend Discount
Gordon GGM
$8.89
$17.71
$26.82
67
DDM Multi-Stage
$8.89
$14.92
$18.70
67
Multiples
P/E Multiple
$62.57
$83.43
$104.29
63
P/S Multiple
$48.35
$64.47
$80.59
58
P/B Multiple
$48.35
$64.47
$80.59
55
EV/EBIT
$83.06
$109.60
$136.15
66
EV/EBITDA
$112.92
$149.42
$185.92
67
EV/Revenue
$60.26
$84.62
$108.98
54
Asset-Based
NCAV (Graham)
$19.57
$26.22
$39.14
54
Growth DCF
Growth DCF
$52.77
$76.42
$109.41
78
Rev-Margin DCF
$55.82
$89.22
$128.28
72
Economic Profit
Residual Income
$33.76
$36.91
$45.19
76
ROIC Compounder
$51.38
$64.13
$79.75
72
Growth Earnings
Growth-Adj P/E
$52.76
$75.37
$97.98
67
Notify me when BMXMF reaches fair value
Put BMXMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
69/100
Of which business quality 67 · Market factors (momentum, volatility) 32
Profitability
52
Margins and returns on capital today
Quality Growth
46
Are margins and returns improving?
Cashflow
65
Earnings quality: real cash, not paper profit
Fin. Strength
86
Balance sheet, leverage, solvency risk
Investment
77
Disciplined investing over empire-building
Low Volatility
57
Calm price path (market factor)
Momentum
27
Price trend over the last 3–12 months (market factor)
52W Momentum
14
Distance to the 52-week high (market factor)
Net Issuance
80
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.4%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.4% vs 11.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 16%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +3.8% a year for the price and +2.5% for the forecasts.
Forecast 2026 (sales)+1.1%
Forecast 2027 (sales)+6.5%
Projected 2028 (sales)+5.9%
Projected 2029 (sales)+5.4%
Projected 2030 (sales)+4.8%
Watch BMXMF, get fair value alerts →
Earlier news
News mood ⓘNews mood, the average tone of recent news (37 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Positive
Recent news coverage is more positive than average.
- BioMerieux SA (BMXMF) (Q2 2026) Earnings Call Highlights: Strong Cash Flow and Strategic ...
- bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
- BioMerieux SA (BMXMF) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and ...
- bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality
Compare bioMérieux S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $675.05 | $686.04 | +2% |
| Danaher Corporation DHR | $221.55 | $209.18 | −6% |
| WuXi AppTec Co 603259 | ¥162.40 | ¥178.64 | +10% |
| Agilent Technologies, Inc A | $175.03 | $64.17 | −63% |
| Lonza Group LONN | CHF 565.60 | CHF 151.69 | −73% |
| IQVIA Holdings IQV | $270.37 | $297.41 | +10% |
| Waters Corporation WAT | $433.54 | $106.46 | −75% |
| Illumina, Inc ILMN | $271.90 | $295.60 | +9% |
| IDEXX Laboratories, Inc IDXX | $533.44 | $495.84 | −7% |
| Mettler-Toledo International Inc MTD | $1,512 | $644.24 | −57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is bioMérieux S.A (BMXMF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $83.43 versus a price of $85.00, about −2% upside (fairly valued).
What is the fair value of BMXMF?
Our model-based fair value for bioMérieux S.A is $83.43 (as of Oct 3, 2026), built from audited fundamentals. The current price: $85.00.
What is the quality score of BMXMF?
bioMérieux S.A has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for bioMérieux S.A (BMXMF)?
Our model-based price target is the fair value of $83.43 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario $57.55, optimistic scenario $104.29. It is a calculation from audited fundamentals, not an analyst target.
What is the bioMérieux S.A stock forecast for 2026?
Our models put fair value at $83.43, about −2% upside versus a price of $85.00 (fairly valued). Cautious scenario $57.55, optimistic scenario $104.29. The calculation is refreshed regularly with new filings.
What is the revenue of bioMérieux S.A (BMXMF)?
bioMérieux S.A reported trailing-twelve-month revenue of about €4.1B (latest available figure, as of Oct 3, 2026).
Does bioMérieux S.A pay a dividend?
bioMérieux S.A currently shows a dividend yield of about 1.15% relative to its recent price (as of Oct 3, 2026).
What growth is priced into bioMérieux S.A (BMXMF)?
For today's price to be fair in a discounted-cash-flow model, bioMérieux S.A would have to grow free cash flow by +6.1 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of BMXMF use?
Our models discount bioMérieux S.A at 8.7 %: a base by market capitalisation (mid), damped by beta 0.56, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For bioMérieux S.A that is +6.1 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has bioMérieux S.A (BMXMF) delivered so far?
Over the past 5 years revenue at bioMérieux S.A grew +5.5 % a year. The price currently implies +6.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of bioMérieux S.A (BMXMF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into bioMérieux S.A (+6.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of bioMérieux S.A (BMXMF)?
The free-cash-flow yield on the price is 5.04 %: that much free cash flow bioMérieux S.A produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of bioMérieux S.A (BMXMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For bioMérieux S.A it is $83.43 per share (as of Oct 3, 2026), against a price of $85.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is bioMérieux S.A stock overvalued or undervalued in 2026?
As of Oct 3, 2026, BMXMF trades above its calculated fair value: price $85.00, fair value $83.43, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMXMF?
No. The price is what the market pays today ($85.00); the fair value is what the company's own numbers justify ($83.43). For bioMérieux S.A the two are $1.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is bioMérieux S.A worth?
The market values bioMérieux S.A at about $10.1B (market capitalisation, as of Oct 3, 2026). Per share that is $85.00; our models calculate a fair value of $83.43 per share.
What do the bullish and bearish scenarios say about BMXMF?
Our models span a range for bioMérieux S.A: cautious scenario $57.55, base $83.43, optimistic $104.29 per share (as of Oct 3, 2026, price $85.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BMXMF?
bioMérieux S.A trades at a price-to-earnings ratio of 21.9 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $83.43 is built from several models across several years. Other multiples: PEG 1.2, P/B 2.2, P/S 2.3, EV/EBITDA 7.8.
What is the PEG ratio of BMXMF?
The PEG ratio of bioMérieux S.A is 1.24 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of bioMérieux S.A (BMXMF)?
Balance-sheet figures for bioMérieux S.A (as of Oct 3, 2026): return on equity 9.5%, debt of 0.05 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is BMXMF from its 52-week high?
bioMérieux S.A trades at $85.00, about 35% below its 52-week high of $130.53 and 12% above the low of $76.22 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $83.43 is for.
Which stocks are comparable to bioMérieux S.A?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is bioMérieux S.A stock attractive at the current price?
The data as of Oct 3, 2026: price $85.00, calculated fair value $83.43 (−2%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMXMF calculated?
We run bioMérieux S.A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $83.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. bioMérieux S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of bioMérieux S.A (BMXMF)?
The closing price on Oct 2, 2026 was $85.00. Our model-based fair value is $83.43, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with bioMérieux S.A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($57.55 to $104.29) leaves room in how you read the outcome.
Where does the earnings growth of bioMérieux S.A (BMXMF) come from?
Earnings per share at bioMérieux S.A grew +12.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.1 %, EBIT margin +2.2 %, tax rate +1.0 %, residual (interest, one-offs) +0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of bioMérieux S.A
How large is the market capitalisation of bioMérieux S.A (BMXMF)?
The market capitalisation of bioMérieux S.A is $10.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of bioMérieux S.A (BMXMF)?
The price-to-sales ratio of bioMérieux S.A is 2.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of bioMérieux S.A (BMXMF)?
Earnings per share at bioMérieux S.A are $3.88 (price ÷ EPS = P/E 21.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of bioMérieux S.A (BMXMF)?
The dividend yield of bioMérieux S.A is 1.2% (payout 25.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of bioMérieux S.A (BMXMF)?
The net margin of bioMérieux S.A is 9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of bioMérieux S.A (BMXMF)?
The return on equity (ROE) of bioMérieux S.A is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of bioMérieux S.A (BMXMF)?
On an EBIT basis the return on assets of bioMérieux S.A is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of bioMérieux S.A (BMXMF)?
The operating margin of bioMérieux S.A is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at bioMérieux S.A (BMXMF)?
Revenue at bioMérieux S.A is growing −2.5% versus a year earlier (3y avg +4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at bioMérieux S.A (BMXMF)?
Earnings per share at bioMérieux S.A are growing +9.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does bioMérieux S.A (BMXMF) hold?
bioMérieux S.A holds more cash than debt, €108M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch bioMérieux S.A in the live analysis
One click puts bioMérieux S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.